Stephen M. Stahl

This extensively revised second edition provides a user-friendly step-by-step manual on the range of psychotropic medications prescribed for children and adolescents by clinicians and nurse practitioners. Boasting nearly double the medications of the first edition, it features new sections related to pharmacokinetics and pharmacogenetics in children and adolescents alongside algorithms for addressing frequently encountered disorders such as anxiety, depression, bipolar disorder, ADHD, and OCD. Based on the best-seller, Stahl's Prescriber's Guide, and using a full-color template-driven navigation system, it combines evidence-based data with clinically informed guidance to support prescribers in the field. Each drug is presented in the same classic design format with illustrated guidance on dosing, titration, and pharmacogenetics/metabolism. Color-coded sections distinguish clearly the information presented on therapeutics, safety and tolerability, dosing and use, what to expect, and the art of psychopharmacology, and are followed by updated and new key references. A must-have guide for all mental health professionals.

With the range of psychotropic drugs expanding and the usages of existing medications diversifying, we are pleased to present the Eighth Edition of the world's best-selling formulary in psychopharmacology. The new edition features seven brand new compounds as well as information about several newly approved formulations of existing drugs. Many important new indications are covered for existing drugs, as are updates to the profiles of the entire content and collection, including new injectable and transdermal formulations, as well as updated warnings and indications. The icons and Pearls have been refreshed throughout, and with the book's its easy-to-use, full-colour template-driven navigation system, Prescriber's Guide combines evidence-based data with clinically informed advice to support everyone who is prescribing in the field of mental health.

With the range of psychotropic drugs expanding and the usages of existing medications diversifying, we are pleased to present the Eighth Edition of the world's best-selling formulary in psychopharmacology. The new edition features seven brand new compounds as well as information about several newly approved formulations of existing drugs. Many important new indications are covered for existing drugs, as are updates to the profiles of the entire content and collection, including new injectable and transdermal formulations, as well as updated warnings and indications. The icons and Pearls have been refreshed throughout, and with the book's its easy-to-use, full-colour template-driven navigation system, Prescriber's Guide combines evidence-based data with clinically informed advice to support everyone who is prescribing in the field of mental health.

Mental health professionals routinely make treatment decisions without necessarily having an overarching perspective about optimal next steps. This important new book provides them with reader-friendly, pragmatic strategies to approach clinical problems as testable hypotheses. It discusses how to apply concepts based on decision analytic theory using risk-benefit analyses, contingency planning, measurement-based care, shared decision making, pharmacogenetics, disease staging, and machine learning. Readers will learn how these tools can help them craft optimal pharmacological and psychosocial interventions tailored to the needs of an individual patient. The book covers topics such as diagnostic ambiguity, interview technique, applying statistical concepts to individual patients, artificial intelligence, and managing high-risk, treatment-resistant, or demanding and difficult patients. Valuable clinical vignettes are featured throughout the book to illustrate common dilemmas and scenarios where the relative merits of competing treatment options invite a more iterative than definitive approach. For all healthcare professionals who prescribe psychotropic medications.

This brand-new fourth volume in Stahl's Case Studies series presents a selection of clinical case studies in child and adolescent psychopharmacology, taken from Dr. Strawn's clinics and consultations. These cases illustrate common questions that are routinely asked by Dr. Strawn's peers in consultations and which represent dilemmas in the day-to-day practice of pediatric psychopharmacology. Followings a consistent, user-friendly layout, each case features icons, tips and questions about diagnosis and management as it progresses over time, a pre-case self-assessment question, followed by the correct answers at the end of the case. Formatted in alignment with the American Board of Psychiatry and Neurology's maintenance of psychiatry speciality certification, cases address multifaceted issues in a relevant and understandable way. Covering a wide-ranging and representative selection of clinical scenarios, each case is followed through the complete clinical encounter, from start to resolution, acknowledging all the complications, issues, decisions, twists and turns along the way.

Worldwide efforts to promote greater lithium use for mood disorders have increased the need for evidence-based guidance addressing key questions related to initiation, monitoring and adverse effect management. This practical handbook provides clinicians with a detailed explanation of lithium's renal journey, how this informs our understanding of polyuria pathogenesis and how medications or hyponatremia can alter lithium clearance. Covering efficacy, pharmacokinetics, toxicity, discontinuation, and use in special patient groups including pregnant and breastfeeding women, older or younger patients, each section also provides a detailed background for its suggested logical approach to managing lithium's renal and other adverse effects. Using the latest data, the book outlines rationales for specific management decisions, and prioritizes options to provide clinical guidance on the best course of action. Colour-coded lists and tables, bulleted text, and diagrams illustrate important points throughout, helping to make information accessible and easy-to-digest. An essential resource for mental health professionals worldwide.

Clinicians recognize that monitoring psychotropic levels provides invaluable information to optimize therapy and track treatment adherence, but they lack formal training specifically focused on the use of plasma antipsychotic levels for these purposes. As new technologies emerge to rapidly provide these results, the opportunity to integrate this information into clinical care will grow. This practical handbook clarifies confusing concepts in the literature on use of antipsychotic levels, providing clear explanations for the logic underlying clinically relevant concepts such as the therapeutic threshold and the point of futility, and how these apply to individual antipsychotics. It offers accessible information on the expected correlation between dosages and trough levels, and also provides a clear explanation of how to use antipsychotic levels for monitoring oral antipsychotic adherence, and methods to help clinicians differentiate between poor adherence and variations in drug metabolism. An essential resource for psychiatrists, psychiatric nurse practitioners, and mental health professionals worldwide.

Despite the lack of guidance available for practitioners, extensive polypharmacy has become the primary method of treating patients with severe and chronic mood, anxiety, psychotic or behavioral disorders. This ground-breaking new book provides an overview of psychopharmacology knowledge and decision-making strategies, integrating findings from evidence-based trials with real-world clinical presentations. It adopts the approach and mind-set of a clinical investigator and reveals how prescribers can practice 'bespoke psychopharmacology', tailoring care to the individualized needs of patients. Practitioners at all levels of expertise will enhance their ability to devise rationale-based treatments, targeting manifestations of dysfunctional neural circuitry and dimensions of psychopathology that cut across conventional psychiatric diagnoses. Presented in a user-friendly, practical, full-colour layout and incorporating summary tables, bullet points, and illustrative case vignettes, it is an invaluable guide for all healthcare professionals prescribing psychotropic medications, including psychiatry specialists, primary care physicians, and advanced practice registered nurses.

With the range of psychotropic drugs expanding and the usages of existing medications diversifying, we are pleased to present the Seventh Edition of the world's best-selling formulary in psychopharmacology. The new edition features nine new compounds as well as information about several new formulations of existing drugs. Many important new indications are covered for existing drugs, as are updates to the profiles of the entire content and collection, including new injectable and transdermal formulations, as well as updated warnings and indications. The Pearls have all been refreshed and the antipsychotics section has been completely revised. With its easy-to-use, full-colour template-driven navigation system, Prescriber's Guide combines evidence-based data with clinically informed advice to support everyone who is prescribing in the field of mental health.

With the range of psychotropic drugs expanding and the usages of existing medications diversifying, we are pleased to present the Seventh Edition of the world's best-selling formulary in psychopharmacology. The new edition features nine new compounds as well as information about several new formulations of existing drugs. Many important new indications are covered for existing drugs, as are updates to the profiles of the entire content and collection, including new injectable and transdermal formulations, as well as updated warnings and indications. The Pearls have all been refreshed and the antipsychotics section has been completely revised. With its easy-to-use, full-colour template-driven navigation system, Prescriber's Guide combines evidence-based data with clinically informed advice to support everyone who is prescribing in the field of mental health.

Real-world and clinical trial data support that clozapine is the only effective antipsychotic for treatment resistant schizophrenia and other severe mental illnesses. Clozapine also reduces rates of suicidality, psychiatric hospitalization and all-cause mortality. However, clozapine is underutilized for two reasons: misunderstandings of its efficacy benefits and misapprehension of, limited knowledge or misinformation about the management of treatment related risks and adverse effects. In response to worldwide efforts to promote clozapine use, this user-friendly Handbook provides clinicians with evidence-based approaches for patient management, as well as logical approaches to the management of clinical situations and adverse effects. It outlines clearly the rationale for specific management decisions and prioritises the options based on this logic. This Handbook is designed for use by clinicians worldwide and is essential reading for all mental health care professionals.

Child and adolescent psychopharmacology is a rapidly growing field with psychotropic medications used widely in the treatment of this patient group. However, psychopharmacological treatment guidelines used for adults cannot simply be applied for children or adolescents, thus presenting clinicians and nurse practitioners with assessment and prescribing challenges. Based on the best-selling resource Stahl's Prescriber's Guide, this new book provides a user-friendly step-by-step manual on the range of psychotropic drugs prescribed for children and adolescents by clinicians and nurse practitioners. Reviewed by expert Child and Adolescent Psychiatrists, the medications are presented in the same design format in order to facilitate rapid access to information. Each drug is broken down into a number of sections, each designated by a unique color background thereby clearly distinguishing information presented on therapeutics, safety and tolerability, dosing and use, what to expect, special populations, and the art of psychopharmacology, and followed by key references.

This spin-off from Stephen M. Stahl's new, completely revised, and fully updated sixth edition of the Prescriber's Guide covers the most important drugs in use today for treating patients suffering from psychotic illness. Now established as the indispensable formulary in psychopharmacology, easy to navigate and easy to use, the Prescriber's Guide combines evidence-based information with clinically informed guidance to support clinicians in making the most effective prescribing decisions for the good of their patients. Incorporating information on the newest indications, new formulations, new recommendations and new safety data, this edition continues to provide the essential practical support required by anyone prescribing in the field of mental health.

This spin-off from Stephen M. Stahl's new, completely revised, and fully updated sixth edition of the Prescriber's Guide covers the most important drugs in use today for treating depression. Now established as the indispensable formulary in psychopharmacology, easy to navigate and easy to use, the Prescriber's Guide combines evidence-based information with clinically informed guidance to support clinicians in making the most effective prescribing decisions for the good of their patients. Incorporating information on the newest indications, new formulations, new recommendations and new safety data, this edition continues to provide the essential practical support required by anyone prescribing in the field of mental health.

Following the success of the first collection of Stahl's Case Studies, published in 2011, we are pleased to present this completely new selection of clinical stories. Designed with the distinctive user-friendly presentation readers have become accustomed to and making use of icons, questions/answers and tips, these cases address complex issues in an understandable way and with direct relevance to the everyday experience of clinicians. Covering a wide-ranging and representative selection of clinical scenarios, each case is followed through the complete clinical encounter, from start to resolution, acknowledging all the complications, issues, decisions, twists and turns along the way. The book is about living through the treatments that work, the treatments that fail, and the mistakes made along the journey. This is psychiatry in real life - these are the patients from your waiting room - this book will reassure, inform and guide better clinical decision making. Optional posttests with CME credit are available for a fee (waived for NEI members). For more information, contact the Neuroscience Education Institute.

Designed with the distinctive, user-friendly presentation Dr Stahl's audience know and love, this new stream of Stahl books capitalize on Dr Stahl's greatest strength - the ability to address complex issues in an understandable way and with direct relevance to the everyday experience of clinicians. The book describes a wide-ranging and representative selection of clinical scenarios, making use of icons, questions/answers and tips. It follows these cases through the complete clinical encounter, from start to resolution, acknowledging all the complications, issues, decisions, twists and turns along the way. The book is about living through the treatments that work, the treatments that fail, and the mistakes made along the journey. This is psychiatry in real life – these are the patients from your waiting room – this book will reassure, inform and guide better clinical decision making.

In response to rapid developments in psychopharmacology, this is a spin-off from Stephen M. Stahl's new, completely revised and updated third edition of his much-acclaimed Prescriber's Guide. It covers the most important drugs in use today for psychosis and mood stabilization. In full color throughout, and with four or more pages for each of the antipsychotic drugs, Stephen M. Stahl distills his great expertise into a pragmatic formulary that gives all the information a prescriber needs to treat patients effectively. Each drug is covered in five categories: general therapeutics, dosing and use, side effects, special populations, and pearls. Target icons appear next to key categories for each drug so that the prescriber can go easily and instantly to the information needed. Several indices are included, listing drugs by name (generic and international) and use. In addition, Dr Stahl indicates which drugs have FDA approval and also gives the FDA Use-in-Pregnancy ratings.

Relying upon the best-selling third edition of Stahl's Essential Psychopharmacology, Dr Stephen M. Stahl has revised chapters covering depression and bipolar disorder for this edition. Significantly revised and expanded it is essential for professionals treating depression and students needing a straight forward illustrated guide to drug mechanism and current research. It includes advances in neurobiology and recent clinical developments to explain with renewed clarity clinical advances in antidepressant therapy and includes new coverage of sleep disorders and disorders of impulse control. The fully revised text is complemented by many new illustrations and enhanced to reflect new knowledge and topics not covered in the previous edition. More than one-third longer than the previous edition, it is essential reading for professionals treating psychosis and students learning the mechanisms of drug reactions. Intended as a primer text covering all aspects of treatment for psychosis and related conditions, this concise volume can nevertheless be read cover to cover by experts and novices alike. Accreditation and Credit Designation Statements The Neuroscience Education Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Neuroscience Education Institute designates this educational activity for a maximum of 90.0 AMA PRA Category 1 Credits(tm). Physicians should only claim credit commensurate with the extent of their participation in the activity. Sponsorship Information Sponsored by Neuroscience Education Institute Support This activity is supported solely by the sponsor. Neither the Neuroscience Education Institute nor Stephen M. Stahl, MD, PhD has received any funds or grants in support of this educational activity.